2019-11-20 16:12:58
Wei-Feng Zheng1 • Hui-Fang Ma1 • Xue-Wei Chang1 • Shou-Yan Zhang1
Received: 28 August 2018 / Published online: 11 October 2018
Springer Science+Business Media, LLC, part of Springer Nature 2018
AA Blocks offers a number of benzyl bromide products, aablocks offers hard-to-find and hard-to-synthesize products in laboratory quantities as well as bulk quantities.
Introduction
Although great advances have been achieved in the medicine science to tackle any disease, there is still great room to develop new and more effective drugs [1]. This is especially demandable in the treatment of cancer, which causes millions of deaths every year and is a great threat to the human health. For the being now, chemotherapy that relies on the platin-based anticancer drugs such as oxaliplatin, carboplatin and cisplatin suffer from some intrinsic limitations such as high toxicity, undesirable side effects and drug resistance [2]. Thus, various efforts have been made to mitigate the drawbacks of the platin-based anticancer drugs by creation of a variety of analogous coordination compounds [3]. Accordingly, during the last few decades, various metal-based coordination compounds
have been synthesized and studied for the anticancer activities, such as Ir(III), Cu(II) and Co(II)-based coordination compounds [4–6]. Among these complexes, the Co(II) and Cu(II)-based coordination complexes have received particularly attention due to several favorable properties such as various coordination modes, strong binding abilities, cheap starting materials and so on. For instance, Natarajan etal have reported the anticancer activity of a Co(II) coordination polymer toward a series of human cancer cells (HeLa and A431) [5]; Wang et al prepared two Zn(II) and Cu(II)-based coordination polymers on the basis of the same organic ligand, and found that the Cu-based coordination polymer shows much better anticancer activities than the Zn(II)-based one [6].
As an emerging type of coordination complexes, coordination polymers with organic ligands as the connector and metal ion/clusters as connecting blocks, have underwent a booming evolution in the past 20 years [7–9]. The functionality and biocompatibility of these coordination polymers could be finely tuned via selecting proper metal ions and organic ligands. Among these coordination polymers, the transition metal ones have been largely studied in the fields of biomedicine applications because these transition metal ions are physiologically integrant metal elements that play important roles in the endogenous oxidative DNA damage of cancer and replace other important metals in enzymes at high concentrations [10–12]. All the above mentioned characters make these materials promising candidates for the anticancer studies.
Although some transition metal coordination polymers have been studied for inhibiting human tumor growth, less attention has been paid to their anticancer activities as a function of micro/nanoscale architectures. As anticancer drugs, the coordination polymer in nanoscale region could facilitate the release of drugs to the whole body and absorbed by the specific tissues by intravenous administration. In this study, two new coordination polymers [Co2(L)2(4,40-bipy)(H2O)2](DMA)2 (1, H2L = 4-(1Hpyrazole-4-yl)benzoic acid, 4,40-bipy = 4,40-bipyridine) and [Cu2(L)2(4,40-bipy)](DEF)3 (2, DEF = N, N-diethylformamide), have been synthesized via solvothermal reaction of M(NO3)26H2O (M = Co for 1 and Cu for 2) with the pyrazolate/carboxylate ligand and the 4,40-bipy linker, which show interesting diversiform framework structures depending on the template organic solvents and the metal salts used. The as-prepared coordination polymer 1 reveals a 3D pillared-layer framework based on the 1D
Cu(II) chain-like secondary building unit that connected by the l2-H2O molecules, while complex 2 reveals a twofold interpenetrated 3D pillared-layer framework based on a binuclear {Cu(II)}2 secondary building unit. Furthermore, both coordination polymer architectures in nanoscale regimes have been prepared, and the cytotoxicity of these nano coordination polymers against the human cardiac myoma cells H9C2 has been evaluated via the MTT assay with the cisplatin as the reference drug, which demonstrates better anticancer activities of the both nano architectures than those of their samples in micro regimes.
Experimental
Measurement and Reagents
Elemental analyses (C, H, N) were performed on Vario EL III Elementar analyzer instrument. The exact particle sizes for the two as-prepared two nano coordination polymers have been probed via the high resolution transmission electron microscopy (JEOL 3010). Expert Pro (Phillips) X-ray diffractometer with Cu Ka was used to collect the PXRD patterns. Unless otherwise noted, all the chemicals are commercially available and used without further purification.
Preparations of [Co2(L)2(4,40-bipy)(H2O)2](DMA)2(1) and [Cu2(L)2(4,40-bipy)](DEF)3 (2) Into a 50 mL breaker was added Co(NO3)26H2O (0.15 mmol, 45 mg), H2L (0.1 mmol, 19 mg) and DMA (5 mL). After the addition of three drops of HCl (aq, 1 M), the mixture (pH = 5.6) was violently stirred for 30 min with heating to make a clear solution. Then the methanolic solution (2 ml) containing 4,40-bipy ligand (0.05 mmol, 8 mmg) was added into the breaker and further stirred for 20 min. Then the solution was placed into a 20 mL of glass vial. The vial was kept at 100 C using the constant temperature oven for three days. Green block products of 1 were formed on the bottom of the glass vial after the oven was left to room temperature, cleaned by MeOH and dried in the air. Yield: 46.6% on the basis of the H2L ligand.
Anal. Calcd. (%) for 1 C38H42Co2N8O8: H, 4.89; N, 12.94; C, 52.71; Found: H, 4.96; N, 13.08. C, 52.99. IR for 1 (KBr pellet, cm-1): 3356 (br, bridging H2O), 1607 (s, C=O), 1532 (s), 1406 (s), 1322 (m), 1187 (m), 1027 (s), 950 (w), 860 (w), 786 (w), 701 (w), 664 (w) and 508 (w).
Into a 50 mL breaker was added Cu(NO3)26H2O (0.15 mmol, 36 mg), H2L (0.1 mmol, 19 mg) and DEF (6 mL). After the addition of three drops of HCl (aq, 1 M), the mixture the mixture (pH = 6.2) was violently stirred for 30 min with heating to make a clear solution. Then the methanolic solution (2 ml) containing 4,40-bipy ligand (0.05 mmol, 8 mmg) was added into the breaker and further stirred for 20 min. Then the solution was placed into a 20 mL of glass vial. The vial was kept at 100 C using the constant temperature oven for three days. Green cubic products of 1 were formed on the bottom of the glass vial after the oven was left to room temperature, cleaned by MeOH and dried in the air. Yield: 52.9% on the basis of the H2L ligand. Anal. Calcd. (%) for 1 C45H53Cu2N9O7: H, 5.57; N, 13.14 C, 56.36; Found: H, 5.78; C, 56.12; N, 13.26. IR for 2 (KBr pellet, cm-1): 3316 (br), 1607 (s), 1555 (s), 1397 (s), 1321 (m), 1193 (m), 1028 (w), 948 (w), 861 (w), 797 (w), 704 (w), 657 (w) and 502(w).
Synthetic Procedure for the Nanoparticles of 1 and 2 M(NO3)26H2O (1.5 mmol) was dissolved in DMA (DEF for 2) (40.0 mL) and added to a mixture of polyvinylpyrrolidone (PVP) DMA (DEF for 2) solution
(11.2 g, 40.0 mL). After a few minutes of stirring, the organic ligands were added to this solution. The obtained solution was mixed under vigorous stirring for 2 h at room temperature under ultrasonic radiation. Afterwards, it was left overnight at 60 C. The mixtures were precipitated with 80 mL acetone to yield green suspension, isolated by centrifugation at 4000 rpm for 15 min and washed with MeOH (100.0 mL) several times to yield the targeted products.
Single-Crystal X-ray Diffraction
The crystal data for the both complexes were acquired on the Bruker APEX II diffractometer at room temperature. After the data collection, the raw data was reduced via the SAINT program to obtain the HKL file. The initial structural modes of the two complexes were obtained via the SHELXT program and then refined by the SHELXL program based on the full matrix least-squares refinements. All H atoms attached to the C atoms were treated with the AFIX commends. All non-H atoms were dealt with anisotropic parameters. Table 1 shows the crystal data and structural refinements parameters for complexes 1 and 2.
Antitumor Activity
The viability of complexes treated cells ware measured by MTT assay method. Into a 96-well plate (TPP, St. Louis, MO) was added the targeted human cardiac myoma cells H9C2 with a cell density of 5000 cells/well, and kept at 37 C for 24 h under the humidified atmosphere containing 95% air and 5% CO2 before the addition of the two coordination polymers. Then DMSO was added to dissolve the compounds and diluted in the respective medium containing 1% FBS. After incubation for 24 h, the medium containing the coordination polymers was removed followed by the addition of the MTT solution (20 lL, 6 mg/ mL in PBS) into each well and kept for another 4 h. Then the supernatant was replaced with 150 lL of dimethyl sulfoxide (DMSO) each well, following by monitored using a microplate reader at 490 nm.
Results and Discussion
Description of the Crystal Structures The Co(II)-coordination polymer 1 could be obtained via a solvothermal reaction of Co(NO3)26H2O, H2L and 4,40-bipy ligands in the acidified DMA solution. It should be noted that only insolvable green precipitation is obtained without the addition of HCl. From the X-ray single crystal analysis results, it could be found that complex 1 behaves as the orthorhombic crystal system, space group Pbcn with a Z value of 8 and could be described as a 3D pillared-layer framework. The molecular building cell of 1 contains two crystallographically independent Co2? ions, two l2-bridging water molecules, one L2- ligand and two 4,40-bipy ligands, which all contribute to a neutral framework structure. As shown in the Fig. 1a, both of the Co(II) ions in the asymmetric unit of 1 reveal the same coordination surrounds, which are both hexa-coordinated with one O atoms from the L2- ligand, two l2-bridging water molecules and three N donor sites from two 4,40-bipy linkers and one coordinated L2- ligand, which shape the distorted octahedral geometry with [CoO3N3] coordination environment. The distances of Co–O bonds are in the range of 1.992(3) to 2.116(3) A˚ and the Co–N bond distances vary from 2.154(4) to 2.178(4) A˚ , which are all comparable with other Co(II)-MOFs in the literature [13–15]. The adjacent Co2? ions are connected by the l2-bridging water molecules and the syn-bridging carboxylic groups along the [001] direction to give rise to the 1D rod-shaped Co(II) secondary building unit chains with the Co1–Co2 distance of 3.600 A˚ . The 1D Co(II) chains are further connected with each other via the L2- ligands along the bc plane to shape the two-dimensional layered network, which are further pillared via the 4,40-bipy ligands to give rise to the 3D pillar layered network with 1D quadrate pores running along the [001] direction (Fig. 1b). The effective window size for 1 is 12.484 9 9.849 A˚ 2 with the consideration of the van der Waals radius (Fig. 1c). The PLATON analysis reveals a total solvent accessible volume of 3554 A˚ 3, corresponding 44% of the cell volume. The simplification of the network of 1 via the software TOPOS indicates that the structure of 1 could be represented as a (3,7)-connected net with the point symbol of {3.5^2}{3^2.4^4.5^7.6^7.7} by considering the 4,40-bipy ligand as 2-connected node, binuclear Co2? cluster as 7-connected node and the pyrazol ring as a 3-connected node, which has not reported so far according to the TOPOS database [16] (Fig. 1d).
The synthesis approach of coordination polymer 2 was similar to that of coordination polymer 1, except that the DMA was replaced by the DEF solvents. It has been reported that the solvents used in the solvothermal reaction could behave as templates in the formation of the targeted coordination polymers, and different structures with various secondary building units could be obtained by using
different solvents [17]. The structural determination of 2 via the X-ray single crystal study reveals that complex 2 locates in the orthorhombic crystal system, space group Pnna with a Z value of 8 and shows a twofold interpenetrated pillared-layer network. The asymmetric unit of 2 contains two independent Cu2? ions, a L2- linker and two 4,40-bipy ligands, which all contribute to a neutral framework structure. The two Cu2? ions in the molecular units show the same coordinating surroundings with the tetra coordinated Cu2? ion sharping the distorted tetrahedral geometry with CuN3O surrounding (Fig. 2a). The Cu-N bond distances lie in the region of 1.976(3) to 2.011(2) A˚ and the Cu-O bond distance is 1.932(3) A˚ . The Cu2 and Cu1 atoms are token together by three pyrazole groups on the L2- ligands to afford the binuclear {Cu2} cluster, which serves as the secondary building unit in the formation of 2 (Fig. 2b). The L2- ligand binds with three Cu2? ion (carboxylate in monodentate fashion and pyrazole in bidentate fashion) in the ab plane to afford grid layer motifs with rhombus windows, and such 2D layers are further connected by the 4,40-bipy ligands to afford the 3D ? 3D twofold interpenetrated framework structure (Fig. 2c). The TOPOS analysis demonstrates that complex 2 could be represented as a uninodal 5-connected net with the point symbol of {4^4.6^6} by considering the organic
ligands as 2-connected linkers and the {Cu2} cluster as 6-connected nodes, which belongs to the sqp-type topology (Fig. 2d).
We use the air-dried powdered samples of the two complexes to collect the powder X-ray diffractions (PXRD) for checking their phase purity. As shown in Fig. 3, the homogeneity between the simulated patterns and the collected patterns verifies the successful preparation of the pure compounds.
Downsizing the Particles of the Two Coordination Polymers
It has been previously reported that the coordination polymer nanocrystals could be achieved by addition of PVP in the reaction systems. With this in mind, PVP was added into the reaction system of complexes 1-2 and the successful realization of the nano-crystals was confirmed by scanning electron microscope images and powder X-ray diffractions. It seems that ultrasonic radiation and PVP
played a vital role in the morphology development of the nano/micro-crystals. It has been indicated that PVP acts not only as a shape and size controller but also as a stabilizer [18]. SEM images of nano 1 prepared by sonochemical process show the nano rods morphology with a thickness of 185 nm. For nano 2, the average dimensions of the formed cubic particles are approximately 70 nm (Fig. 4).
Anticancer Activity
The similar framework compositions but different metal centers of the complexes 1 and 2 encourage us to study their cytotoxicity against the human cardiac myoma cells H9C2 via the strand MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay method. The asprepared coordination polymers 1 and 2 were dispersed in DMSO solution with different concentrations (from 10-40 lg/mL) and blank samples with the equal amount of DMSO were prepared as controls. As shown in Fig. 5a, the cell lines treated with the both complexes show cancer cell inhibiting growth effect with the Cu(II)-based complex 2 showing better anticancer activity, indicating the Cu(II)-based coordination polymer shows stronger anticancer activities than the Co(II)-based coordination polymer. Such a phenomenon might be attributed to the different functionality of these metal ions. It has been reported that the Cu(II) ion could participate in hydrolysis, dioxygen transport and reduction of nitrogen oxides, which are all in concern with the cancer cell death [19–22]. Furthermore, to study the size effect on the anticancer activity of the two complexes, the cytotoxicity of the nano-1 and nano-2 has also been studied via the MTT assay with the cancer drug cisplation as the positive control. As shown in the Fig. 5b, it could be observed that the anticancer activity of complexes 1 and 2 is greatly boosted via forming the nano particle. It is worth to mention that the anticancer activity of the nano-2 is comparable with cisplatin, which indicates its potential use as anticancer drugs in the future.
Conclusion
In conclusion, this work has confirmed that the mixedligand approach is a good choice for the formation of coordination polymers with diversiform structures and different building blocks by building two novel coordination polymers. The X-ray single crystal studies reveal that complex 1 could be described as a 3D pillared-layer framework based on the 1D Cu(II) chain-like secondary building unit that connected by the l2-H2O molecules, while complex 2 reveals a twofold interpenetrated threedimensional pillar-layered network based on a binuclear {Cu(II)}2 secondary building unit. Furthermore, the MTT
assay indicates that the anticancer activities of the as-prepared two coordination polymers are greatly enhanced by downsizing into nano regions. The present research might bring new insights into the development of transition metal based anticancer drugs for targeted application in the future.
5,7-Difluoro-3-methyl-1-benzofuran-2-carboxylic acidCatalog No.:AA01A1KR CAS No.:1019111-84-2 MDL No.:MFCD09965712 MF:C10H6F2O3 MW:212.1496 |
7-bromo-5-chloro-3-methyl-1-benzofuran-2-carboxylic acidCatalog No.:AA01A88T CAS No.:1019111-85-3 MDL No.:MFCD09965715 MF:C10H6BrClO3 MW:289.5098 |
3-amino-2-{[2-(trifluoromethyl)phenyl]methyl}propan-1-olCatalog No.:AA019XVS CAS No.:1019113-91-7 MDL No.:MFCD11126627 MF:C11H14F3NO MW:233.2302 |
4-(3,5-difluorobenzamido)-2-hydroxybenzoic acidCatalog No.:AA019WKW CAS No.:1019114-54-5 MDL No.:MFCD11978177 MF:C14H9F2NO4 MW:293.2224 |
4-Fluoro-2-(pentyloxy)anilineCatalog No.:AA00H9LF CAS No.:1019114-95-4 MDL No.:MFCD09811884 MF:C11H16FNO MW:197.2492 |
1,7-Naphthyridine-5-carboxylic acidCatalog No.:AA01ARBK CAS No.:1019115-06-0 MDL No.:MFCD09863863 MF:C9H6N2O2 MW:174.1561 |
2-(4-Fluorobenzamido)-5,6-dihydro-4h-cyclopenta[d]thiazole-4-carboxylic acidCatalog No.:AA01AS04 CAS No.:1019115-34-4 MDL No.:MFCD09864120 MF:C14H11FN2O3S MW:306.3121 |
2-Amino-n-ethyl-1,3-thiazole-4-carboxamideCatalog No.:AA01ARAJ CAS No.:1019115-37-7 MDL No.:MFCD09864134 MF:C6H9N3OS MW:171.2202 |
7-bromo-3-methyl-1-benzofuran-2-carboxylic acidCatalog No.:AA01A5WQ CAS No.:1019115-67-3 MDL No.:MFCD09965716 MF:C10H7BrO3 MW:255.0648 |
2-Bromo-5-ethoxybenzene-1-sulfonyl chlorideCatalog No.:AA01BRCX CAS No.:1019115-70-8 MDL No.:MFCD09880304 MF:C8H8BrClO3S MW:299.5693 |
3-amino-2-[(3-fluorophenyl)methyl]propan-1-olCatalog No.:AA019SBS CAS No.:1019116-42-7 MDL No.:MFCD11126524 MF:C10H14FNO MW:183.2227 |
2-(BENZOYLAMINO)-5,6-DIHYDRO-4H-CYCLOPENTA[D][1,3]THIAZOLE-4-CARBOXYLIC A+Catalog No.:AA01ARB4 CAS No.:1019117-26-0 MDL No.:MFCD09864119 MF:C14H12N2O3S MW:288.3217 |
Benzothiazole, 2-bromo-4,6-difluoro-Catalog No.:AA0005UU CAS No.:1019117-36-2 MDL No.:MFCD09748544 MF:C7H2BrF2NS MW:250.0633 |
(1,2,5-trimethyl-1H-pyrrol-3-yl)methanamineCatalog No.:AA01AM4N CAS No.:1019117-62-4 MDL No.:MFCD09965840 MF:C8H14N2 MW:138.2102 |
3-amino-2-{[4-(trifluoromethoxy)phenyl]methyl}propan-1-olCatalog No.:AA01A116 CAS No.:1019119-11-9 MDL No.:MFCD11126223 MF:C11H14F3NO2 MW:249.2296 |
(3-Isothiocyanato-2,2-dimethylpropyl)dimethylamineCatalog No.:AA01A9LU CAS No.:1019119-63-1 MDL No.:MFCD11131125 MF:C8H16N2S MW:172.2910 |
2-[3-(Trifluoromethyl)phenoxy]pyridine-3-carbonitrileCatalog No.:AA01C0I4 CAS No.:1019119-96-0 MDL No.:MFCD12550587 MF:C13H7F3N2O MW:264.2027 |
2-[(2-oxo-1,3-oxazolidin-3-yl)methyl]benzonitrileCatalog No.:AA01AHOB CAS No.:1019120-04-7 MDL No.:MFCD11131219 MF:C11H10N2O2 MW:202.2093 |
1-(azepan-1-yl)-2-[(propan-2-yl)amino]ethan-1-oneCatalog No.:AA01BAHJ CAS No.:1019121-12-0 MDL No.:MFCD11129196 MF:C11H22N2O MW:198.3052 |
4-(1,3,4-Thiadiazol-2-ylsulfanyl)anilineCatalog No.:AA01A79F CAS No.:1019121-55-1 MDL No.:MFCD11132429 MF:C8H7N3S2 MW:209.2913 |
2-(1,3,4-thiadiazol-2-ylsulfanyl)anilineCatalog No.:AA01A8JI CAS No.:1019121-56-2 MDL No.:MFCD24712022 MF:C8H7N3S2 MW:209.2913 |
3-Chloro-2-[(4-methyl-1,3-thiazol-2-yl)sulfanyl]anilineCatalog No.:AA01A81F CAS No.:1019121-58-4 MDL No.:MFCD11132441 MF:C10H9ClN2S2 MW:256.7749 |
3-Amino-n-methyl-1h-1,2,4-triazole-5-carboxamideCatalog No.:AA008VE2 CAS No.:1019126-62-5 MDL No.:MFCD18064612 MF:C4H7N5O MW:141.1313 |
2-(2-Methylpiperidin-1-yl)isonicotinic acidCatalog No.:AA01A8LP CAS No.:1019127-10-6 MDL No.:MFCD11131978 MF:C12H16N2O2 MW:220.2676 |
2-(Cyclopentylamino)isonicotinic acidCatalog No.:AA0005UR CAS No.:1019127-19-5 MDL No.:MFCD11132015 MF:C11H14N2O2 MW:206.2411 |
2-(4,5,6,7-Tetrahydro-1-benzothiophen-2-ylformamido)acetic acidCatalog No.:AA01A9IX CAS No.:1019127-35-5 MDL No.:MFCD11130303 MF:C11H13NO3S MW:239.2908 |
methyl 2-[(3,4-difluorophenyl)(hydroxy)methyl]prop-2-enoateCatalog No.:AA01A68S CAS No.:1019127-48-0 MDL No.:MFCD11130338 MF:C11H10F2O3 MW:228.1921 |
N-Methyl-n-[3-(1,3,5-trimethyl-1h-pyrazol-4-yl)propyl]amineCatalog No.:AA008SST CAS No.:1019130-43-8 MDL No.:MFCD06804139 MF:C10H19N3 MW:181.2780 |
1-[(4-bromophenyl)methyl]-1H-1,2,4-triazol-3-amineCatalog No.:AA01A80V CAS No.:1019150-05-0 MDL No.:MFCD12766726 MF:C9H9BrN4 MW:253.0986 |
7-(4-methylphenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-oneCatalog No.:AA00J0JY CAS No.:1019152-04-5 MDL No.:MFCD11999513 MF:C13H10N2OS MW:242.2963 |
2-(4-methoxyphenyl)-1-{[5-(2-nitrophenyl)furan-2-yl]methyl}pyrrolidineCatalog No.:AA00ILA6 CAS No.:1019158-02-1 MDL No.:MFCD14826567 MF:C22H22N2O4 MW:378.4211 |
sodiuM 4-pentynoateCatalog No.:AA008TGU CAS No.:101917-30-0 MDL No.:MFCD22417092 MF:C5H5NaO2 MW:120.0818 |
Bisphenol a diacetateCatalog No.:AA0005VW CAS No.:10192-62-8 MDL No.:MFCD00026194 MF:C19H20O4 MW:312.3597 |
Potassium acrylateCatalog No.:AA0005VV CAS No.:10192-85-5 MDL No.:MFCD00067206 MF:C3H3KO2 MW:110.1530 |
Regorafenib monohydrateCatalog No.:AA008TGK CAS No.:1019206-88-2 MDL No.:MFCD17170366 MF:C21H17ClF4N4O4 MW:500.8307 |
Manganocene, 1,1'-diethyl-Catalog No.:AA0005VM CAS No.:101923-26-6 MDL No.:MFCD01862452 MF:C14H18Mn MW:241.2308 |
4-Phenylpyridin-3-olCatalog No.:AA0005VK CAS No.:101925-26-2 MDL No.:MFCD04114251 MF:C11H9NO MW:171.1953 |
H-Nva-NH2 HClCatalog No.:AA0005VJ CAS No.:101925-47-7 MDL No.:MFCD00237404 MF:C5H13ClN2O MW:152.6225 |
2-hydrazino-5-methyl-4-(2-thienyl)pyrimidineCatalog No.:AA00J2JW CAS No.:1019257-99-8 MDL No.:MFCD28977335 MF:C9H10N4S MW:206.2675 |
2-IODOPROPANE-D7Catalog No.:AA008SX8 CAS No.:101927-33-7 MDL No.:MFCD00134435 MF:C3D7I MW:177.0353 |
Acetic acid, 2-mercapto-, 1,1'-(1,4-butanediyl) esterCatalog No.:AA0005WK CAS No.:10193-95-0 MDL No.:MFCD00266655 MF:C8H14O4S2 MW:238.3244 |
Trimethylolpropane Tris(thioglycolate)Catalog No.:AA003CMT CAS No.:10193-96-1 MDL No.:MFCD00046836 MF:C25H21N3O3S MW:443.5175 |
Pentaerythritol tetrakis(2-mercaptoacetate)Catalog No.:AA0035DO CAS No.:10193-99-4 MDL No.:MFCD00022080 MF:C13H20O8S4 MW:432.5531 |
(R)-(+)-1-Benzyl-3-pyrrolidinolCatalog No.:AA0005WE CAS No.:101930-07-8 MDL No.:MFCD00075484 MF:C11H15NO MW:177.2429 |
Hydroxy Pioglitazone (M-II) (Mixture of Diastereomers)Catalog No.:AA008W2A CAS No.:101931-00-4 MDL No.:MFCD00871962 MF:C19H20N2O4S MW:372.4381 |
1-Naphthalenemethanamine, 4-methoxy-Catalog No.:AA0005W7 CAS No.:101931-31-1 MDL No.:MFCD06213084 MF:C12H13NO MW:187.2377 |
Manganocene, 1,1',2,2',3,3',4,4'-octamethyl- (9CI)Catalog No.:AA0005WR CAS No.:101932-75-6 MDL No.:MFCD01862454 MF:C18H26Mn MW:297.3371 |
2-(4-Ethylpiperazino)isonicotinic acidCatalog No.:AA00H9LN CAS No.:1019323-95-5 MDL No.:MFCD11132193 MF:C12H17N3O2 MW:235.2823 |
5-chloro-6-[(1-methyl-1H-imidazol-2-yl)sulfanyl]pyridine-3-carboxylic acidCatalog No.:AA01A91P CAS No.:1019324-90-3 MDL No.:MFCD11132219 MF:C10H8ClN3O2S MW:269.7074 |
N-(1,3,4-Thiadiazol-2-yl)piperidine-3-carboxamideCatalog No.:AA019VGT CAS No.:1019324-93-6 MDL No.:MFCD11128708 MF:C8H12N4OS MW:212.2721 |
N-methyl-2-(methylamino)-N-(pyridin-2-yl)acetamideCatalog No.:AA01A8YS CAS No.:1019325-08-6 MDL No.:MFCD11128717 MF:C9H13N3O MW:179.2190 |
4-chloro-2-(5-methylthiophen-2-yl)quinazolineCatalog No.:AA01AA8X CAS No.:1019325-36-0 MDL No.:MFCD11127020 MF:C13H9ClN2S MW:260.7420 |
2-chloro-1,5-hexadieneCatalog No.:AA01CCGZ CAS No.:101933-88-4 MDL No.: MF:C6H9Cl MW:116.5887 |
2-Chloro-N-({4-[2-(cyanosulfamoyl)phenyl]phenyl}methyl)-N-[(4-methylphenyl)methyl]benzamideCatalog No.:AA0005XN CAS No.:1019331-10-2 MDL No.:MFCD23136018 MF:C29H24ClN3O3S MW:530.0372 |
1-(4-Chlorobenzyl)piperidin-3-aminesulfateCatalog No.:AA01FO4L CAS No.:1019331-35-1 MDL No.: MF:C12H19ClN2O4S MW:322.8083 |
1-(3-Phenylpropyl)piperidin-3-amine sulfateCatalog No.:AA01FO4U CAS No.:1019331-36-2 MDL No.: MF:C14H24N2O4S MW:316.4164 |
1-(4-Isobutylbenzyl)piperidin-3-amine sulfateCatalog No.:AA01FO4M CAS No.:1019331-38-4 MDL No.: MF:C16H28N2O4S MW:344.4695 |
1-(1-Cyclohexylpiperidin-3-yl)-N-(pyridin-3-ylmethyl)methanamine sulfateCatalog No.:AA01FO4N CAS No.:1019331-40-8 MDL No.: MF:C18H31N3O4S MW:385.5214 |
4-Chloro-7-hydroxy-6-Methoxy-7-quinolineCatalog No.:AA0093RN CAS No.:1019340-49-8 MDL No.:MFCD03411531 MF:C14H16O4 MW:248.2744 |
2-[4-(aminomethyl)piperidin-1-yl]-N-tert-butylacetamideCatalog No.:AA019YE4 CAS No.:1019340-98-7 MDL No.:MFCD11131481 MF:C12H25N3O MW:227.3464 |
(1-butylpiperidin-2-yl)methanamineCatalog No.:AA01A82L CAS No.:1019341-68-4 MDL No.:MFCD11131551 MF:C10H22N2 MW:170.2951 |
1-(cyclopropylmethyl)-2-oxo-2,3-dihydro-1H-1,3-benzodiazole-5-carboxylic acidCatalog No.:AA01EKCA CAS No.:1019342-55-2 MDL No.:MFCD11131631 MF:C12H12N2O3 MW:232.2353 |
2-oxo-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-1,3-benzodiazole-5-carboxylic acidCatalog No.:AA01A0FQ CAS No.:1019342-70-1 MDL No.:MFCD11523455 MF:C10H7F3N2O3 MW:260.1694 |
4-Hydroxy-n-(2,2,2-trifluoroethyl)benzamideCatalog No.:AA01AA3A CAS No.:1019343-45-3 MDL No.:MFCD11130986 MF:C9H8F3NO2 MW:219.1605 |
2-(4-(pyridin-4-ylmethoxy)phenyl)acetic acidCatalog No.:AA01BTIZ CAS No.:1019344-27-4 MDL No.:MFCD11523467 MF:C14H13NO3 MW:243.2579 |
2-[4-(2-methoxyethoxy)phenyl]acetic acidCatalog No.:AA01BDM8 CAS No.:1019344-55-8 MDL No.:MFCD11131696 MF:C11H14O4 MW:210.2265 |
N-(2-carbamothioylethyl)-N-methylacetamideCatalog No.:AA01A29W CAS No.:1019345-48-2 MDL No.:MFCD11130020 MF:C6H12N2OS MW:160.2373 |
3-methyl-2-(4-methylphenyl)piperidineCatalog No.:AA01AJXJ CAS No.:1019345-69-7 MDL No.:MFCD11128070 MF:C13H19N MW:189.2967 |
2-Bromo-3-nitrophenolCatalog No.:AA0005XU CAS No.:101935-40-4 MDL No.:MFCD08704555 MF:C6H4BrNO3 MW:218.0049 |
2-(Ethylsulfanyl)aniline hydrochlorideCatalog No.:AA00J36V CAS No.:101935-45-9 MDL No.:MFCD12912784 MF:C8H12ClNS MW:189.7056 |
5-chloro-2-[(2,2,2-trifluoroethyl)sulfanyl]anilineCatalog No.:AA01AJTM CAS No.:1019350-70-9 MDL No.:MFCD11128871 MF:C8H7ClF3NS MW:241.6611 |
Methyl 4-aminopiperidine-1-carboxylateCatalog No.:AA0005XI CAS No.:1019351-46-2 MDL No.:MFCD11128922 MF:C7H14N2O2 MW:158.1983 |
2-[(3-Methylbut-2-en-1-yl)sulfanyl]benzoic acidCatalog No.:AA01AKH0 CAS No.:1019351-72-4 MDL No.:MFCD11127705 MF:C12H14O2S MW:222.3034 |
2-{4-methyl-2-[(2-methylpropyl)sulfanyl]-1,3-thiazol-5-yl}acetic acidCatalog No.:AA01C3W6 CAS No.:1019352-39-6 MDL No.:MFCD11128512 MF:C10H15NO2S2 MW:245.3616 |
3-(4-amino-3-methylphenoxy)oxolan-2-oneCatalog No.:AA01BH91 CAS No.:1019352-80-7 MDL No.:MFCD11129337 MF:C11H13NO3 MW:207.2258 |
2-{2-[(2-chloroprop-2-en-1-yl)sulfanyl]-4-methyl-1,3-thiazol-5-yl}acetic acidCatalog No.:AA01C3XV CAS No.:1019352-89-6 MDL No.:MFCD11128536 MF:C9H10ClNO2S2 MW:263.7642 |
2-(Cyclohexyloxy)isonicotinic acidCatalog No.:AA009MWD CAS No.:1019353-19-5 MDL No.:MFCD09258836 MF:C12H15NO3 MW:221.2524 |
2-[(3-hydroxyphenyl)formamido]acetamideCatalog No.:AA01AII9 CAS No.:1019353-72-0 MDL No.:MFCD11130775 MF:C9H10N2O3 MW:194.1873 |
3-[(2-cyanoethyl)(phenyl)carbamoyl]propanoic acidCatalog No.:AA01AA9Z CAS No.:1019354-66-5 MDL No.:MFCD11522997 MF:C13H14N2O3 MW:246.2619 |
tert-Butyl n-(2-amino-1-[4-(propan-2-yl)phenyl]ethyl)carbamateCatalog No.:AA01AAO2 CAS No.:1019355-17-9 MDL No.:MFCD11584357 MF:C16H26N2O2 MW:278.3898 |
(4-CHLOROPHENYL)(2-METHYLPHENYL)METHANAMINECatalog No.:AA01EJBJ CAS No.:1019355-69-1 MDL No.:MFCD11127104 MF:C14H14ClN MW:231.7207 |
Ethyl 4-chloro-6-fluoro-8-methylquinoline-3-carboxylateCatalog No.:AA01AKKE CAS No.:1019355-72-6 MDL No.:MFCD11522696 MF:C13H11ClFNO2 MW:267.6833 |
8-Chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinolineCatalog No.:AA0005XH CAS No.:1019356-62-7 MDL No.:MFCD11126887 MF:C10H9ClF3N MW:235.6334 |
2-((2,5-Dichlorophenyl)amino)nicotinonitrileCatalog No.:AA00H9LQ CAS No.:1019357-51-7 MDL No.:MFCD11127196 MF:C12H7Cl2N3 MW:264.1101 |
3-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]propanoic acidCatalog No.:AA019K9B CAS No.:1019357-65-3 MDL No.:MFCD11107672 MF:C13H13NO4 MW:247.2466 |
2-chloro-4-(pyrrolidine-1-carbonyl)phenolCatalog No.:AA01A2KE CAS No.:1019361-97-7 MDL No.:MFCD06987688 MF:C11H12ClNO2 MW:225.6715 |
3-Hydroxy-n,n,4-trimethylbenzamideCatalog No.:AA019UCY CAS No.:1019362-93-6 MDL No.:MFCD11131088 MF:C10H13NO2 MW:179.2157 |
1-[(2-Methylpropoxy)carbonyl]piperidine-4-carboxylic acidCatalog No.:AA01A983 CAS No.:1019363-04-2 MDL No.:MFCD11128990 MF:C11H19NO4 MW:229.2729 |
1-(Methoxycarbonyl)piperidine-3-carboxylic acidCatalog No.:AA01AATS CAS No.:1019363-10-0 MDL No.:MFCD11128996 MF:C8H13NO4 MW:187.1931 |
6-((4-Methoxyphenyl)thio)pyridin-3-amineCatalog No.:AA00IRRA CAS No.:1019363-45-1 MDL No.:MFCD11132352 MF:C12H12N2OS MW:232.3015 |
3-Chloro-2-(pyridin-2-ylsulfanyl)anilineCatalog No.:AA01A8ND CAS No.:1019363-62-2 MDL No.:MFCD11132366 MF:C11H9ClN2S MW:236.7206 |
2-[2-(cyclopentylsulfanyl)-4-methyl-1,3-thiazol-5-yl]acetic acidCatalog No.:AA01C3GN CAS No.:1019363-64-4 MDL No.:MFCD11128522 MF:C11H15NO2S2 MW:257.3723 |
2-(2,4-difluorophenoxy)pyridine-4-carboxylic acidCatalog No.:AA01BF6B CAS No.:1019364-36-3 MDL No.:MFCD11522815 MF:C12H7F2NO3 MW:251.1857 |
2-[(4-hydroxyphenyl)formamido]acetamideCatalog No.:AA01AIJK CAS No.:1019364-95-4 MDL No.:MFCD11130785 MF:C9H10N2O3 MW:194.1873 |
4-[(4-methyl-1,3-thiazol-2-yl)sulfanyl]anilineCatalog No.:AA019VD2 CAS No.:1019365-00-4 MDL No.:MFCD11132439 MF:C10H10N2S2 MW:222.3298 |
1-cyclopropyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazole-5-carboxylic acidCatalog No.:AA01B6LE CAS No.:1019367-66-8 MDL No.:MFCD11131637 MF:C11H10N2O3 MW:218.2087 |
2-{4-[(methylcarbamoyl)methoxy]phenyl}acetic acidCatalog No.:AA01A975 CAS No.:1019369-12-0 MDL No.:MFCD11131697 MF:C11H13NO4 MW:223.2252 |
Diethyl 2-(((4-bromophenyl)amino)methylene)malonateCatalog No.:AA0005XR CAS No.:101937-44-4 MDL No.:MFCD00173358 MF:C14H16BrNO4 MW:342.1851 |
2-([(4-Chlorophenyl)amino]carbonyl)cyclohexanecarboxylic acidCatalog No.:AA0005XQ CAS No.:101937-67-1 MDL No.:MFCD00590283 MF:C14H16ClNO3 MW:281.7347 |
6-[(cyclopropylmethyl)amino]pyridine-3-carboxylic acidCatalog No.:AA01BFLN CAS No.:1019372-31-6 MDL No.:MFCD11132056 MF:C10H12N2O2 MW:192.2145 |
2-(3-Chlorophenoxy)-3-methylbutanoic acidCatalog No.:AA01A41S CAS No.:1019372-32-7 MDL No.:MFCD11127004 MF:C11H13ClO3 MW:228.6721 |
2-(Benzylamino)isonicotinic acidCatalog No.:AA009KSI CAS No.:1019372-91-8 MDL No.:MFCD11132066 MF:C13H12N2O2 MW:228.2466 |
4-(2,6-Difluorophenyl)piperidineCatalog No.:AA01AFCN CAS No.:1019373-70-6 MDL No.:MFCD11047470 MF:C11H13F2N MW:197.2244 |
N-Benzyl-1-(6-methylpyridin-2-yl)methanamineCatalog No.:AA0005XO CAS No.:101938-10-7 MDL No.:MFCD08144088 MF:C14H16N2 MW:212.2902 |
{1-[(3-chlorophenyl)methyl]piperidin-2-yl}methanamineCatalog No.:AA01AGYZ CAS No.:1019380-49-4 MDL No.:MFCD11131546 MF:C13H19ClN2 MW:238.7564 |
(1-propylpiperidin-2-yl)methanamineCatalog No.:AA01DUU9 CAS No.:1019380-53-0 MDL No.:MFCD11131557 MF:C9H20N2 MW:156.2685 |
{1-[2-(dimethylamino)ethyl]piperidin-4-yl}methanamineCatalog No.:AA019X8X CAS No.:1019381-31-7 MDL No.:MFCD11131485 MF:C10H23N3 MW:185.3097 |
[1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl]methanamineCatalog No.:AA01ADBD CAS No.:1019381-67-9 MDL No.:MFCD11131522 MF:C7H13F3N2 MW:182.1867 |
2-chloro-N-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)propanamideCatalog No.:AA019KOD CAS No.:1019382-22-9 MDL No.:MFCD11127003 MF:C10H8ClF2NO3 MW:263.6252 |
N-(3-aminopropyl)-N-methylethane-1-sulfonamideCatalog No.:AA019U4E CAS No.:1019383-00-6 MDL No.:MFCD11129788 MF:C6H16N2O2S MW:180.2684 |
2-(2,3-dihydro-1H-indene-5-amido)thiophene-3-carboxylic acidCatalog No.:AA01AAQ7 CAS No.:1019383-42-6 MDL No.:MFCD13563551 MF:C15H13NO3S MW:287.3336 |
2-(methylamino)-N-(4-methylpyridin-2-yl)acetamideCatalog No.:AA01A99C CAS No.:1019383-78-8 MDL No.:MFCD11131873 MF:C9H13N3O MW:179.2190 |
2-((tert-Butoxycarbonyl)amino)-4-fluorobenzoic acidCatalog No.:AA01BS5Z CAS No.:1019384-47-4 MDL No.:MFCD02682188 MF:C12H14FNO4 MW:255.2423 |
3-bromo-4-(dimethylsulfamoyl)benzoic acidCatalog No.:AA01AARS CAS No.:1019384-91-8 MDL No.:MFCD11131893 MF:C9H10BrNO4S MW:308.1490 |
5,8-dichloro-1,2,3,4-tetrahydroquinolineCatalog No.:AA01C1SE CAS No.:1019385-18-2 MDL No.:MFCD11126881 MF:C9H9Cl2N MW:202.0805 |
N-(3-methylpyridin-2-yl)piperidine-3-carboxamideCatalog No.:AA019VFR CAS No.:1019385-37-5 MDL No.:MFCD11128700 MF:C12H17N3O MW:219.2829 |
N-(1,3,4-thiadiazol-2-yl)piperidine-4-carboxamideCatalog No.:AA019VGS CAS No.:1019385-44-4 MDL No.:MFCD11128707 MF:C8H12N4OS MW:212.2721 |
3-Oxo-3-(4,5,6,7-tetrahydro-1-benzothiophen-2-yl)propanenitrileCatalog No.:AA01C5IP CAS No.:1019385-55-7 MDL No.:MFCD11130328 MF:C11H11NOS MW:205.2761 |
1-[2-(4-amino-3-methylphenoxy)ethyl]imidazolidin-2-oneCatalog No.:AA01B882 CAS No.:1019386-58-3 MDL No.:MFCD11128269 MF:C12H17N3O2 MW:235.2823 |
2-(Isopropylamino)-5-nitrobenzoic acidCatalog No.:AA00ITLD CAS No.:1019387-83-7 MDL No.:MFCD11131983 MF:C10H12N2O4 MW:224.2133 |
6-[(2,2,2-trifluoroethyl)amino]pyridine-3-carboxylic acidCatalog No.:AA01BFMT CAS No.:1019388-10-3 MDL No.:MFCD11132208 MF:C8H7F3N2O2 MW:220.1486 |
2-methylpropyl N-(3-aminophenyl)carbamateCatalog No.:AA019XCT CAS No.:1019388-96-5 MDL No.:MFCD11128933 MF:C11H16N2O2 MW:208.2569 |
5-chloro-2-[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]anilineCatalog No.:AA01A853 CAS No.:1019390-35-2 MDL No.:MFCD11132293 MF:C8H8ClN5S MW:241.7006 |
3-chloro-4-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]anilineCatalog No.:AA01A8EO CAS No.:1019390-95-4 MDL No.:MFCD11132379 MF:C9H9ClN4S MW:240.7126 |
(4-([5-(Trifluoromethyl)pyridin-2-yl]thio)phenyl)amineCatalog No.:AA00H9M1 CAS No.:1019391-05-9 MDL No.:MFCD11132350 MF:C12H9F3N2S MW:270.2735 |
3-chloro-4-[(4-methyl-1,3-thiazol-2-yl)sulfanyl]anilineCatalog No.:AA01A9A9 CAS No.:1019391-52-6 MDL No.:MFCD11132438 MF:C10H9ClN2S2 MW:256.7749 |
2-[(2,5-dimethylphenyl)sulfanyl]anilineCatalog No.:AA01EJDS CAS No.:1019391-62-8 MDL No.:MFCD11132446 MF:C14H15NS MW:229.3406 |
4-(4-[(3-Methylbut-2-en-1-yl)oxy]phenyl)butan-2-oneCatalog No.:AA019X0X CAS No.:1019392-34-7 MDL No.:MFCD11127727 MF:C15H20O2 MW:232.3181 |
5-Methyl-2-(2-oxopyrrolidin-1-yl)benzoic acidCatalog No.:AA01AHHK CAS No.:1019394-58-1 MDL No.:MFCD11127759 MF:C12H13NO3 MW:219.2365 |
2-chloro-N-(2-cyanoethyl)-N-methylpropanamideCatalog No.:AA018RVD CAS No.:1019394-83-2 MDL No.:MFCD11129445 MF:C7H11ClN2O MW:174.6280 |
3-[(2H-1,3-benzodioxol-5-yloxy)methyl]anilineCatalog No.:AA019V0K CAS No.:1019395-25-5 MDL No.:MFCD11131653 MF:C14H13NO3 MW:243.2579 |
(4-CHLOROPHENYL)(3-METHYLPHENYL)METHANAMINECatalog No.:AA01EJBL CAS No.:1019395-84-6 MDL No.:MFCD11127111 MF:C14H14ClN MW:231.7207 |
(3-Aminopropyl)(methyl)(2,2,2-trifluoroethyl)amineCatalog No.:AA019NEI CAS No.:1019397-28-4 MDL No.:MFCD11130122 MF:C6H13F3N2 MW:170.1760 |
N-[4-(aminomethyl)phenyl]-4-butylcyclohexane-1-carboxamideCatalog No.:AA01A9PB CAS No.:1019400-32-8 MDL No.:MFCD13563484 MF:C18H28N2O MW:288.4277 |
ethyl 4-iodo-5-methyl-1H-pyrazole-3-carboxylateCatalog No.:AA01EL4N CAS No.:1019403-26-9 MDL No.:MFCD22192683 MF:C7H9IN2O2 MW:280.0630 |
2-[4-(propan-2-yl)phenoxy]pyridine-4-carboxylic acidCatalog No.:AA01BS4R CAS No.:1019403-63-4 MDL No.:MFCD12445231 MF:C15H15NO3 MW:257.2845 |
2-[(Cyclohexylmethyl)sulfanyl]pyridine-3-carboxylic acidCatalog No.:AA01AIJJ CAS No.:1019437-73-0 MDL No.:MFCD11127471 MF:C13H17NO2S MW:251.3446 |
5-bromo-2-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]anilineCatalog No.:AA01A8OG CAS No.:1019441-45-2 MDL No.:MFCD11132382 MF:C9H9BrN4S MW:285.1636 |
3-chloro-4-(1,3,4-thiadiazol-2-ylsulfanyl)anilineCatalog No.:AA01AA9G CAS No.:1019441-76-9 MDL No.:MFCD11132428 MF:C8H6ClN3S2 MW:243.7363 |
2-(4-Bromophenoxy)-3-(trifluoromethyl)pyridineCatalog No.:AA01AA6J CAS No.:1019441-79-2 MDL No.:MFCD10703539 MF:C12H7BrF3NO MW:318.0893 |
4-(4-Aminophenoxy)-3-methoxybenzonitrileCatalog No.:AA01A8PP CAS No.:1019441-94-1 MDL No.:MFCD11132457 MF:C14H12N2O2 MW:240.2573 |
5-Bromo-2-(propan-2-yloxy)anilineCatalog No.:AA0005YC CAS No.:1019442-22-8 MDL No.:MFCD11132974 MF:C9H12BrNO MW:230.1017 |
7-isothiocyanato-3,4-dihydro-2H-1,5-benzodioxepineCatalog No.:AA01A9VN CAS No.:1019442-90-0 MDL No.:MFCD11131105 MF:C10H9NO2S MW:207.2490 |
tert-Butyl n-[1-(piperidin-2-yl)ethyl]carbamateCatalog No.:AA019V2B CAS No.:1019442-92-2 MDL No.:MFCD11131129 MF:C12H24N2O2 MW:228.3312 |
3-[(3-aminophenyl)methyl]-1,3-oxazolidin-2-oneCatalog No.:AA019UI5 CAS No.:1019443-34-5 MDL No.:MFCD11131192 MF:C10H12N2O2 MW:192.2145 |
2-(3-Trifluoromethylphenoxy)methylpiperidineCatalog No.:AA0005YB CAS No.:1019443-66-3 MDL No.:MFCD13272699 MF:C13H16F3NO MW:259.2674 |
2-Bromo-4-fluoro-1-(2-fluorobenzyloxy)benzeneCatalog No.:AA0005YA CAS No.:1019446-40-2 MDL No.:MFCD11127639 MF:C13H9BrF2O MW:299.1108 |
3-(Cyclohexylmethoxy)benzaldehydeCatalog No.:AA009MWC CAS No.:1019446-59-3 MDL No.:MFCD11127670 MF:C14H18O2 MW:218.2915 |
2-[4-(cyanomethoxy)phenyl]acetic acidCatalog No.:AA01AH33 CAS No.:1019446-81-1 MDL No.:MFCD11131694 MF:C10H9NO3 MW:191.1834 |
2-chloro-N-(2-phenoxyphenyl)propanamideCatalog No.:AA019KN8 CAS No.:1019448-46-4 MDL No.:MFCD12550149 MF:C15H14ClNO2 MW:275.7302 |
2-(4-ethylbenzamido)thiophene-3-carboxylic acidCatalog No.:AA019V6E CAS No.:1019449-40-1 MDL No.:MFCD12165959 MF:C14H13NO3S MW:275.3229 |
4-chloro-2-(3-methoxyphenyl)quinazolineCatalog No.:AA01AA8W CAS No.:1019449-61-6 MDL No.:MFCD12444995 MF:C15H11ClN2O MW:270.7136 |
5-(4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1,3,4-oxadiazol-2-amineCatalog No.:AA019XGH CAS No.:1019450-61-3 MDL No.:MFCD11130319 MF:C10H11N3OS MW:221.2788 |
2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}pyridine-3-carboxylic acidCatalog No.:AA01A9JG CAS No.:1019452-29-9 MDL No.:MFCD11523654 MF:C13H19N3O2 MW:249.3089 |
3-hydroxy-N-(5-methyl-1,3-thiazol-2-yl)benzamideCatalog No.:AA01BARQ CAS No.:1019453-02-1 MDL No.:MFCD11131040 MF:C11H10N2O2S MW:234.2743 |
5-bromo-2-[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]anilineCatalog No.:AA01A81Y CAS No.:1019453-67-8 MDL No.:MFCD11132299 MF:C8H8BrN5S MW:286.1516 |
2-[(2,4-Dimethylphenyl)sulfanyl]anilineCatalog No.:AA0005Y6 CAS No.:1019453-85-0 MDL No.:MFCD11132336 MF:C14H15NS MW:229.3406 |
5-chloro-2-(propan-2-ylsulfanyl)anilineCatalog No.:AA01AAUI CAS No.:1019455-04-9 MDL No.:MFCD11128893 MF:C9H12ClNS MW:201.7163 |
1-[(4-aminophenyl)methyl]-6-chloro-2,3-dihydro-1H-indol-2-oneCatalog No.:AA01A7LX CAS No.:1019456-03-1 MDL No.:MFCD12550358 MF:C15H13ClN2O MW:272.7295 |
2-Chloro-n-1,3,4-thiadiazol-2-ylpropanamideCatalog No.:AA0005Y5 CAS No.:1019456-17-7 MDL No.:MFCD10686620 MF:C5H6ClN3OS MW:191.6386 |
ethyl 4-(2,5-dichlorophenyl)-2,4-dioxobutanoateCatalog No.:AA019XXQ CAS No.:1019457-33-0 MDL No.:MFCD11523433 MF:C12H10Cl2O4 MW:289.1114 |
ethyl 4-(3,4-dimethylphenyl)-2,4-dioxobutanoateCatalog No.:AA019YZB CAS No.:1019457-35-2 MDL No.:MFCD11523438 MF:C14H16O4 MW:248.2744 |
[1-(2-methoxyethyl)pyrrolidin-2-yl]methanamineCatalog No.:AA01AA4D CAS No.:1019457-65-8 MDL No.:MFCD11131512 MF:C8H18N2O MW:158.2413 |
[1-(Propan-2-yl)piperidin-2-yl]methanamineCatalog No.:AA01A1NV CAS No.:1019457-79-4 MDL No.:MFCD11131558 MF:C9H20N2 MW:156.2685 |
[4-(pyridin-4-yl)-1,3-thiazol-2-yl]methanamineCatalog No.:AA01ADAU CAS No.:1019458-83-3 MDL No.:MFCD11129282 MF:C9H9N3S MW:191.2529 |
3-Methyl-2-(5-phenyl-2h-1,2,3,4-tetrazol-2-yl)butanoic acidCatalog No.:AA019WVK CAS No.:1019459-07-4 MDL No.:MFCD11522986 MF:C12H14N4O2 MW:246.2652 |
N-(3-Cyanophenyl)cyclopropanecarboxamideCatalog No.:AA00946J CAS No.:101946-36-5 MDL No.:MFCD03159449 MF:C11H10N2O MW:186.2099 |
2-(Allylamino)isonicotinic acidCatalog No.:AA01FOCO CAS No.:1019461-29-0 MDL No.: MF:C9H10N2O2 MW:178.1879 |
3-Pyridinecarboxylic acid, 2-[(2-methylpropyl)amino]-Catalog No.:AA0005Y3 CAS No.:1019461-50-7 MDL No.:MFCD11106740 MF:C10H14N2O2 MW:194.2304 |
5-chloro-6-(ethylamino)pyridine-3-carboxylic acidCatalog No.:AA01BI1S CAS No.:1019461-54-1 MDL No.:MFCD11132028 MF:C8H9ClN2O2 MW:200.6223 |
(4-chlorophenyl)(4-methylphenyl)methanamineCatalog No.:AA01DX46 CAS No.:1019462-07-7 MDL No.:MFCD11127102 MF:C14H14ClN MW:231.7207 |
1-(4-chlorophenyl)-3,3-dimethylbutan-1-amineCatalog No.:AA01AKNC CAS No.:1019462-15-7 MDL No.:MFCD11127118 MF:C12H18ClN MW:211.7310 |
(2-chloro-4-fluorophenyl)(4-methylphenyl)methanamineCatalog No.:AA01AGMU CAS No.:1019462-46-4 MDL No.:MFCD11127164 MF:C14H13ClFN MW:249.7111 |
N-Cyclopropyl-3-hydroxybenzamideCatalog No.:AA00H9M9 CAS No.:1019466-68-2 MDL No.:MFCD11130687 MF:C10H11NO2 MW:177.1998 |
2-hydroxy-5-methyl-N-(2-methylpropyl)benzamideCatalog No.:AA019WK6 CAS No.:1019466-74-0 MDL No.:MFCD11130699 MF:C12H17NO2 MW:207.2689 |
1H,1H,2H,2H-PerfluorodecyltriethoxysilaneCatalog No.:AA0005YH CAS No.:101947-16-4 MDL No.:MFCD00042334 MF:C16H19F17O3Si MW:610.3786 |
1-(3-fluoro-4-phenoxyphenyl)ethan-1-amineCatalog No.:AA019VTH CAS No.:1019474-96-4 MDL No.:MFCD11137327 MF:C14H14FNO MW:231.2655 |
(2-Hydroxy-3-[2-(trifluoromethyl)phenoxy]propyl)(methyl)amineCatalog No.:AA019WZ5 CAS No.:1019477-18-9 MDL No.:MFCD11135144 MF:C11H14F3NO2 MW:249.2296 |
[(2-bromophenyl)methyl](2-methylbutan-2-yl)amineCatalog No.:AA01AXDM CAS No.:1019477-26-9 MDL No.:MFCD11138894 MF:C12H18BrN MW:256.1820 |
4-[Cyclohexyl(methyl)amino]benzene-1-carboximidamideCatalog No.:AA01A7GP CAS No.:1019478-55-7 MDL No.:MFCD11135314 MF:C14H21N3 MW:231.3366 |
1-[5-fluoro-2-(3-fluorophenoxy)phenyl]ethan-1-oneCatalog No.:AA01E8LC CAS No.:1019479-77-6 MDL No.:MFCD11524227 MF:C14H10F2O2 MW:248.2248 |
8-chloro-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolineCatalog No.:AA01DUUA CAS No.:101948-16-7 MDL No.:MFCD31666858 MF:C12H16ClN MW:209.7151 |
1-[2-(tert-butylsulfanyl)-5-fluorophenyl]ethan-1-oneCatalog No.:AA01BG0U CAS No.:1019480-19-3 MDL No.:MFCD11136968 MF:C12H15FOS MW:226.3103 |
4-Bromo-2-(isobutylaminomethyl)-1-fluorobenzeneCatalog No.:AA0005YY CAS No.:1019480-47-7 MDL No.:MFCD11139638 MF:C11H15BrFN MW:260.1459 |
[(2,4-difluorophenyl)methyl](2-methylpropyl)amineCatalog No.:AA019LPZ CAS No.:1019480-55-7 MDL No.:MFCD11139643 MF:C11H15F2N MW:199.2403 |
3-{[(2-methylpropyl)amino]methyl}phenolCatalog No.:AA00JTOC CAS No.:1019481-37-8 MDL No.:MFCD11139768 MF:C11H17NO MW:179.2588 |
N-[(2,4-difluorophenyl)methyl]cyclopentanamineCatalog No.:AA019LQF CAS No.:1019481-58-3 MDL No.:MFCD11139798 MF:C12H15F2N MW:211.2510 |
N-Cyclopentyl-2-fluoroanilineCatalog No.:AA019S4F CAS No.:1019482-17-7 MDL No.:MFCD11145296 MF:C11H14FN MW:179.2340 |
benzyl[1-(pyridin-2-yl)ethyl]amineCatalog No.:AA01AGFZ CAS No.:1019482-76-8 MDL No.:MFCD11140748 MF:C14H16N2 MW:212.2902 |
[(5-bromo-2-fluorophenyl)methyl](prop-2-en-1-yl)amineCatalog No.:AA01A8F9 CAS No.:1019484-07-1 MDL No.:MFCD11137989 MF:C10H11BrFN MW:244.1034 |
Benzenamine, 5-fluoro-2-(1-methylethoxy)-Catalog No.:AA0005YX CAS No.:1019484-18-4 MDL No.:MFCD11135837 MF:C9H12FNO MW:169.1961 |
5-Fluoro-2-[(1-methyl-1h-imidazol-2-yl)sulfanyl]anilineCatalog No.:AA01A8A2 CAS No.:1019484-54-8 MDL No.:MFCD11135871 MF:C10H10FN3S MW:223.2699 |
5-(benzylsulfanyl)pyridin-2-amineCatalog No.:AA01A2CZ CAS No.:1019484-60-6 MDL No.:MFCD11135878 MF:C12H12N2S MW:216.3021 |
2-(ethylsulfanyl)pyridine-4-carboxylic acidCatalog No.:AA019WTW CAS No.:1019485-25-6 MDL No.:MFCD11136034 MF:C8H9NO2S MW:183.2276 |
5-chloro-6-(cyclopropylmethoxy)pyridine-3-carboxylic acidCatalog No.:AA01A6J1 CAS No.:1019493-16-3 MDL No.:MFCD11136671 MF:C10H10ClNO3 MW:227.6443 |
3-{[(4-chlorophenyl)methyl]amino}benzonitrileCatalog No.:AA019RQ8 CAS No.:1019495-79-4 MDL No.:MFCD11144697 MF:C14H11ClN2 MW:242.7035 |
4-[(butan-2-yl)amino]benzamideCatalog No.:AA01A7MT CAS No.:1019497-02-9 MDL No.:MFCD11143141 MF:C11H16N2O MW:192.2575 |
1-(5-amino-2,3-dihydro-1H-indol-1-yl)-2-methoxyethan-1-oneCatalog No.:AA01AFMO CAS No.:1019498-71-5 MDL No.:MFCD13808927 MF:C11H14N2O2 MW:206.2411 |
(2-methoxyethyl)(1-phenylethyl)amineCatalog No.:AA019LP2 CAS No.:1019499-28-5 MDL No.:MFCD11139348 MF:C11H17NO MW:179.2588 |
2-chloro-N-(2-methylpropyl)anilineCatalog No.:AA01C1YX CAS No.:1019501-43-9 MDL No.:MFCD11145113 MF:C10H14ClN MW:183.6779 |
1-[4-(cyclohexyloxy)-3-fluorophenyl]ethan-1-amineCatalog No.:AA019YRG CAS No.:1019503-62-8 MDL No.:MFCD11137197 MF:C14H20FNO MW:237.3131 |
N-[3-(Dimethylamino)-2,2-dimethylpropyl]-3,4-dihydro-2h-1-benzopyran-4-amineCatalog No.:AA01EHU2 CAS No.:1019505-45-3 MDL No.:MFCD12623679 MF:C16H26N2O MW:262.3904 |
[(2-Chlorophenyl)methyl](cyclopropylmethyl)amineCatalog No.:AA0005YU CAS No.:1019506-73-0 MDL No.:MFCD11140251 MF:C11H14ClN MW:195.6886 |
4-(6-aminopyridin-3-yl)piperazin-2-oneCatalog No.:AA01BD2P CAS No.:1019507-58-4 MDL No.:MFCD11135642 MF:C9H12N4O MW:192.2178 |
1-(6-Nitropyridin-3-yl)piperidin-4-oneCatalog No.:AA01B2LY CAS No.:1019508-29-2 MDL No.:MFCD11135693 MF:C10H11N3O3 MW:221.2126 |
3-ethynyl-N-[(pyridin-4-yl)methyl]anilineCatalog No.:AA01AAEO CAS No.:1019511-94-4 MDL No.:MFCD11138208 MF:C14H12N2 MW:208.2585 |
4-(Cyclopentylamino)benzonitrileCatalog No.:AA0005YQ CAS No.:1019512-92-5 MDL No.:MFCD11145725 MF:C12H14N2 MW:186.2530 |
2,4-difluoro-N-(thiophen-2-ylmethyl)anilineCatalog No.:AA019VUV CAS No.:1019513-80-4 MDL No.:MFCD11145812 MF:C11H9F2NS MW:225.2577 |
2-(cyclopropylmethoxy)propanoic acidCatalog No.:AA009MW4 CAS No.:1019515-23-1 MDL No.:MFCD11136574 MF:C7H12O3 MW:144.1684 |
2-[(4-aminophenyl)methoxy]ethan-1-olCatalog No.:AA01C3RD CAS No.:1019516-04-1 MDL No.:MFCD11136655 MF:C9H13NO2 MW:167.2050 |
(pentan-2-yl)(pentyl)amineCatalog No.:AA019XIW CAS No.:1019518-65-0 MDL No.:MFCD11141204 MF:C10H23N MW:157.2963 |
3-(cyclopropylmethoxy)propanoic acidCatalog No.:AA019YID CAS No.:1019521-50-6 MDL No.:MFCD11136575 MF:C7H12O3 MW:144.1684 |
3-[(Pyridin-2-ylsulfanyl)methyl]anilineCatalog No.:AA01A802 CAS No.:1019522-88-3 MDL No.:MFCD11134012 MF:C12H12N2S MW:216.3021 |
1-[3-fluoro-4-(oxan-2-ylmethoxy)phenyl]ethan-1-amineCatalog No.:AA01A012 CAS No.:1019525-34-8 MDL No.:MFCD11137265 MF:C14H20FNO2 MW:253.3125 |
1-(Phenylmethane)sulfonylpiperidin-3-amineCatalog No.:AA00H9MF CAS No.:1019527-84-4 MDL No.:MFCD11137497 MF:C12H18N2O2S MW:254.3485 |
(butan-2-yl)[2-(2-fluorophenyl)ethyl]amineCatalog No.:AA019LSA CAS No.:1019530-90-5 MDL No.:MFCD11143355 MF:C12H18FN MW:195.2764 |
[(2-bromophenyl)methyl](2-methylpropyl)amineCatalog No.:AA00JTQ6 CAS No.:1019532-08-1 MDL No.:MFCD11139786 MF:C11H16BrN MW:242.1554 |
1-Bromo-2-fluoro-3-(cyclopentylaminomethyl)benzeneCatalog No.:AA0093ZB CAS No.:1019532-16-1 MDL No.:MFCD11139796 MF:C12H15BrFN MW:272.1566 |
1-(CYCLOPENTYLCARBONYL)INDOLIN-6-AMINECatalog No.:AA01ARFF CAS No.:1019533-47-1 MDL No.:MFCD11137570 MF:C14H18N2O MW:230.3055 |
5-amino-2,3-dihydro-1H-indole-1-carboxamideCatalog No.:AA01A283 CAS No.:1019534-31-6 MDL No.:MFCD11137589 MF:C9H11N3O MW:177.2031 |
benzyl[1-(thiophen-2-yl)ethyl]amineCatalog No.:AA019LQK CAS No.:1019534-84-9 MDL No.:MFCD03985208 MF:C13H15NS MW:217.3299 |
4-[(4-Methyl-1,3-thiazol-2-yl)amino]benzene-1-carbothioamideCatalog No.:AA01A8FV CAS No.:1019535-31-9 MDL No.:MFCD11135446 MF:C11H11N3S2 MW:249.3551 |
